RXDX-101: Phase I/IIa started

Ignyta began the open-label, international Phase I/IIa STARTRK-1 trial to evaluate once-daily continuous dosing of RXDX-101 in adults with locally advanced or metastatic cancer with TrkA, ROS1 or ALK ...